Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Invested Capital (2017 - 2025)

Crinetics Pharmaceuticals has reported Invested Capital over the past 9 years, most recently at $992.1 million for Q4 2025.

  • Quarterly results put Invested Capital at $992.1 million for Q4 2025, down 25.11% from a year ago — trailing twelve months through Dec 2025 was $992.1 million (down 25.11% YoY), and the annual figure for FY2025 was $992.1 million, down 25.11%.
  • Invested Capital for Q4 2025 was $992.1 million at Crinetics Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over the last five years, Invested Capital for CRNX hit a ceiling of $1.3 billion in Q4 2024 and a floor of $149.5 million in Q1 2021.
  • Median Invested Capital over the past 5 years was $462.6 million (2022), compared with a mean of $610.4 million.
  • Biggest five-year swings in Invested Capital: crashed 34.19% in 2023 and later surged 226.92% in 2024.
  • Crinetics Pharmaceuticals' Invested Capital stood at $331.9 million in 2021, then decreased by 4.7% to $316.3 million in 2022, then skyrocketed by 70.43% to $539.1 million in 2023, then soared by 145.74% to $1.3 billion in 2024, then decreased by 25.11% to $992.1 million in 2025.
  • The last three reported values for Invested Capital were $992.1 million (Q4 2025), $1.1 billion (Q3 2025), and $1.2 billion (Q2 2025) per Business Quant data.